European Organisation for Research and Treatment of Cancer (EORTC) shared a post on LinkedIn:
“A new study published in Translational Oncology highlights the value of molecular profiling in peritoneal mesothelioma, a rare and aggressive cancer.
Conducted through the EURACAN network and the EORTC SPECTA Arcagen study, the research found actionable alterations in most patients analysed and provides new insights into genomic profiling approaches that can support personalised treatment strategies.
Congratulations to Julien Peron, Nazim Benzerdjeb, Jean-Yves Blay, Marie Morfouace, and all collaborators involved in this work.
Read our news release.”
Other articles from EORTC on OncoDaily.